81 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
and Preclinical Characterization of an Engineered T-Cell Therapy Targeting PRAME-Expressing Solid Tumors” at the American Society of Gene & Cell Therapy
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
31 Jan 24
Other Events
5:07pm
, which met its primary endpoint for efficacy. Data from the trial were presented at the Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Dec 23
Other Events
7:13am
Society (CTOS) 2023 Annual Meeting.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: “With this submission, we have completed a critical step
8-K
EX-99.1
823eduvk 6d
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
u5v8qx5yhg uui7
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
d5l26
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
ok1ol d4kc3xk
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
fuvopdgo62m9ezz6vx
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
semde
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
i63vhieq2p y0
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
4utkr f2ysd
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
we8 dggpr57df2
9 May 22
Adaptimmune Reports First Quarter Financial Results and Business Update
7:40am